Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798877 | 0.90 | IDO1 (0.41) | IDO1TDP1CA12CA1CA2 | |
| SCHEMBL13429387 | 0.78 | IDO1 (0.39) | CACNA1HCACNA1BCACNA1CIDO1TDP1 | |
| SCHEMBL15794060 | 0.77 | HDAC3 (0.37) | GPBAR1CA1CA2MAOAMAOB | |
| SCHEMBL13429272 | 0.77 | SERPINE1 (0.45) | IDO1TDP1CA12CA1CA2 | |
| SCHEMBL8686230 | 0.76 | CACNA1H (0.46) | CACNA1HCACNA1BCACNA1CIDO1TDP1 | |
| SCHEMBL12444075 | 0.75 | NOS1 (0.39) | CFTRMEN1GAAKMT2A | |
| SCHEMBL15794406 | 0.75 | IDO1 (0.43) | CACNA1HCACNA1BCACNA1CIDO1CA12 | |
| SCHEMBL11932050 | 0.74 | HDAC1 (0.40) | IDO1CA1CA2MEN1KMT2A | |
| SCHEMBL13306470 | 0.74 | IDO1 (0.46) | IDO1TDP1CA12CA1CA2 | |
| SCHEMBL24460343 | 0.73 | CFTR (0.47) | GPBAR1CACNA1HCACNA1BCACNA1CIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2709619-B1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | CELLCEUTIX CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-9457027-B2 | Compounds for use in treatment of mucostis | CELLCEUTIX CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | INNOVATION PHARMACEUTICALS INC. | 2016-07-28 | — | — | US | disclosed |
| US-9155738-B2 | Compounds for use in treatment of mucostitis | CELLCEUTIX CORPORATION (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | INNOVATION PHARMACEUTICALS INC. | 2014-12-11 | — | — | US | disclosed |
| US-8802683-B2 | Compounds for use in treatment of mucositis | CELLCEUTIX CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20110178104-A1 | Anti-Heparin Compounds | POLYMEDIX INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011084970-A1 | ANTI-HEPARIN COMPOUNDS | POLYMEDIX INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | GPBAR1 417/4885CACNA1H 4842/4885CACNA1B 4856/4885 |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | MUC1, FUT6, MMP8 | GPBAR1 417/4885CACNA1H 4842/4885CACNA1B 4856/4885 |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | GPBAR1 417/4885CACNA1H 4842/4885CACNA1B 4856/4885 |
| US-20110178104-A1 | Anti-Heparin Compounds | SERPINC1, CFH, SERPINH1 | GPBAR1 3634/4885CACNA1H 786/4885CACNA1B 2594/4885 |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | MUC1, SOST, ALG1 | GPBAR1 959/4885CACNA1H 4363/4885CACNA1B 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.